ライフサイエンスコーパス: pulmonary capillary

1 ormal trafficking of neutrophils through the pulmonary capillaries.

2 es rapid sequestration of neutrophils within pulmonary capillaries.

3 d in the lungs immediately upon reaching the pulmonary capillaries.

4 apid sequestration of neutrophils within the pulmonary capillaries.

5 th ARDS but with a higher thrombus burden in pulmonary capillaries.

6 ally exist in physiological systems, such as pulmonary capillaries.

7 apid sequestration of neutrophils within the pulmonary capillaries 1 min after intravascular injectio

8 increased margination of neutrophils within pulmonary capillaries (39.7 +/- 9.4 vs. 4.6 +/- 1.1 neut

9 s exchange is known to occur proximal to the pulmonary capillary, although the magnitude of this gas

10 determined by electron microscopy imaging of pulmonary capillaries and (125)I-albumin transport from

11 mooth muscle cells, and endothelial cells of pulmonary capillaries and arteries.

12 PECAM-1 in neutrophil emigration across the pulmonary capillaries and the bronchial microvasculature

13 VCAM-1 expression was absent in pulmonary capillaries and unchanged in veins.

14 Pulmonary capillary and pulmonary artery occlusion press

15 trapping of T cells and neutrophils in mouse pulmonary capillaries, and observed neutrophil mobilizat

16 nia, sequestration of neutrophils within the pulmonary capillaries, and release of neutrophils from t

17 ndothelium of the liver and spleen or in the pulmonary capillaries, and was highly dependent on nanop

18 by type II cell hyperplasia, obliteration of pulmonary capillaries, and widespread expression of alph

19 The walls of pulmonary capillaries are extremely thin, and wall stres

20 s and defects in the formation of peripheral pulmonary capillaries as evidenced by significant reduct

21 ment from the carrier b-RBC, probably in the pulmonary capillaries, because lung level of 125I was tw

22 ling pulmonary artery pressure closer to the pulmonary capillary bed and LA pressure closer to the ve

23 emic venous blood to bypass gas exchange and pulmonary capillary bed processing.

24 at allow systemic venous blood to bypass the pulmonary capillary bed through anatomic right-to-left s

25 ion has been proposed to expose parts of the pulmonary capillary bed to high pressure and vascular in

26 n in-house microfluidic device mimicking the pulmonary capillary bed, we show that the dynamics of TH

27 eflect the effects of uniform filling of the pulmonary capillary bed.

28 ce or tissue mechanics, we hypothesized that pulmonary capillary blood flow would increase in associa

29 olar-capillary membrane conductance (DM) and pulmonary capillary blood volume (Vc), were sensitive to

30 ociation with HIB, resulting in increases in pulmonary capillary blood volume (VC).

31 We conclude that pulmonary capillary blood volume does not change followi

32 adient for NO between the alveolar space and pulmonary capillary blood, which results in a decrease i

33 ium results in an almost complete absence of pulmonary capillaries, demonstrating the dependence of p

34 capillaries, demonstrating the dependence of pulmonary capillary development on epithelium-derived Ve

35 vasculature, establishing the dependence of pulmonary capillary development on epithelium-derived Ve

36 iffusing capacity in terms of hematocrit and pulmonary capillary diameter.

37 ng that neutrophil margination in uninfected pulmonary capillaries does not require E- and P-selectin

38 e show that repetitive lung injury activates pulmonary capillary endothelial cells (PCECs) and periva

39 We show that PNX stimulates pulmonary capillary endothelial cells (PCECs) to produce

40 antavirus antigens have been demonstrated in pulmonary capillary endothelial cells, but the mechanism

41 lecule 1 (ICAM-1; CD54) was expressed in the pulmonary capillary endothelium and minimally in the end

42 hypothermic pulmonary artery flushing on the pulmonary capillary filtration coefficient (Kfc), and ad

43 isolated, perfused lung model to measure the pulmonary capillary filtration coefficient and hemodynam

44 hyperinflation lung injury as determined by pulmonary capillary filtration coefficient.

45 of PAH, pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis.

46 Documentation of increased pulmonary capillaries has been shown in models of chroni

47 Pulmonary capillary hemangiomatosis (PCH) is a rare caus

48 factor 2 alpha kinase 4 (EIF2AK4) that cause pulmonary capillary hemangiomatosis and pulmonary veno-o

49 AH and with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis recruited to the Nat

50 and 16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis were recruited.

51 om analysis due to the subsequent finding of pulmonary capillary hemangiomatosis.

52 iagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.

53 escribed in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.

54 pressure (all P <0.01), with no increase in pulmonary capillary hydrostatic pressures.

55 on through tacrolimus pretreatment prevented pulmonary capillary hypertension as well as the activati

56 Pulmonary capillary leak was estimated using radioiodina

57 ssin or norepinephrine limits edema, reduces pulmonary capillary leak, and modulates systemic and pul

58 expression and activity were determined and pulmonary capillary leakage assessed by the Evans blue a

59 remote organ injury as manifested by reduced pulmonary capillary leakage.

60 alk between respiratory epithelial cells and pulmonary capillaries necessary for the formation of the

61 enuded megakaryocyte nuclei were seen in the pulmonary capillaries of mice.

62 Neutrophils in the pulmonary capillaries of rabbits given complement fragme

63 eum, neutrophil emigration across either the pulmonary capillaries or the bronchial microvasculature

64 terized by pulmonary hypertension, increased pulmonary capillary permeability, and hypoxemia.

65 There was a significant increase in pulmonary capillary permeability, wet/dry lung weight ra

66 pathogenic mechanisms of TRALI is increased pulmonary capillary permeability, which results in movem

67 ypothermic modified Euro-Collins solution on pulmonary capillary permeability.

68 compared five literature-based estimates of pulmonary capillary pressure (Ppc) with the correspondin

69 PAOP, mean pulmonary arterial pressure, and pulmonary capillary pressure increased after endotoxin i

70 Oleic acid lung injury increases pulmonary capillary pressure independent of pulmonary ar

71 ure, mean pulmonary arterial pressure, PAOP, pulmonary capillary pressure, and pulmonary arterial and

72 ered mental status and ataxia, and increased pulmonary capillary pressure, and related stress failure

73 nsive-hyperdynamic circulation; increases in pulmonary capillary pressure, net fluid balance, lung an

74 tial contributor to the constant increase in pulmonary capillary pressure.

75 ining the sequestered neutrophils within the pulmonary capillaries required both L-selectin and CD11/

76 mulate neutrophil transit through individual pulmonary capillary segments to determine the relative e

77 parasitized red blood cells were seen inside pulmonary capillaries, suggesting some sequestration in

78 flow rate can alter the size of the perfused pulmonary capillary surface area.

79 through the alveolar-capillary membrane into pulmonary capillaries, through the plasma, and into eryt

80 d to measure right atrial, pulmonary artery, pulmonary capillary wedge and systemic blood pressures.

81 Pulmonary capillary wedge decreased 37% (P=0.009), cardi

82 e average cardiac index increased 89.5%, and pulmonary capillary wedge decreased 52.2%.

83 05 versus placebo for both) without altering pulmonary capillary wedge or mean arterial pressure, hea

84 s in the right atrium, pulmonary artery, and pulmonary capillary wedge positions.

85 ricular ejection fraction 21+/-1%) who had a pulmonary capillary wedge pressure >/=15 mm Hg and a car

86 Patients with a baseline pulmonary capillary wedge pressure >/=15 mm Hg and a car

87 ) >/=15 mm Hg (right ventricular [RV] DD) or pulmonary capillary wedge pressure >/=18 mm Hg (left ven

88 with systolic blood pressure <100 mm Hg and pulmonary capillary wedge pressure >/=24 mm Hg and depen

89 At rest, 10 patients in MI+DD (29%) had pulmonary capillary wedge pressure >15 (14+/-4 mm Hg), w

90 d units, accurately identified patients with pulmonary capillary wedge pressure >15 mm Hg (area under

91 rt database were classified as cold and wet (pulmonary capillary wedge pressure >15 mm Hg) and cold a

92 ropic and intra-aortic balloon pump support, pulmonary capillary wedge pressure >20 mm Hg and serum c

93 esistance > 240 dynes x second x cm(-5), and pulmonary capillary wedge pressure < or = 15 mm Hg.

94 an pulmonary artery pressure >/=25 mm Hg and pulmonary capillary wedge pressure </=15 mm Hg at right

95 ic algorithm for discrimination between mean pulmonary capillary wedge pressure </=15 versus >15 mm H

96 pulmonary arterial pressure >/=25 mm Hg and pulmonary capillary wedge pressure </=15mm Hg).

97 ng goals: central venous pressure <12 mm Hg, pulmonary capillary wedge pressure <18 mm Hg, and cardia

98 venous crystalloid, furosemide, mannitol (if pulmonary capillary wedge pressure <20 mm Hg), and low-d

99 wedge pressure >15 mm Hg) and cold and dry (pulmonary capillary wedge pressure <=15 mm Hg) based on

100 York Heart Association class II-IV, elevated pulmonary capillary wedge pressure (>/=15 mm Hg at rest

101 During exercise, an abnormal rise in pulmonary capillary wedge pressure (>25 mm Hg) was obser

102 vaptan at 20 and 40 mg significantly reduced pulmonary capillary wedge pressure (-2.6+/-0.7, -5.4+/-0

103 ment was associated with lower mean exercise pulmonary capillary wedge pressure (-3 mm Hg [95% CI, -5

104 Inhaled nitrite reduced resting pulmonary capillary wedge pressure (-4+/-3 versus -1+/-2

105 of therapy, net reductions in 0-hour trough pulmonary capillary wedge pressure (-4.3 mm Hg; P=0.16),

106 Tolvaptan at all doses significantly reduced pulmonary capillary wedge pressure (-6.4 +/- 4.1 mm Hg,

107 5.2 +/- 2.4 liters/min, p < 0.01), increased pulmonary capillary wedge pressure (17 +/- 7 vs. 14 +/-

108 -5 versus 4+/-1 mm Hg; P=0.0002), and higher pulmonary capillary wedge pressure (17+/-5 versus 9+/-3

109 essure (149 +/- 16 vs. 108 +/- 14 mm Hg) and pulmonary capillary wedge pressure (18 +/- 2 vs. 12 +/-

110 (22+/-8 versus 11+/-4 mm Hg; P=0.0001), and pulmonary capillary wedge pressure (18+/-5 versus 10+/-4

111 essure (29+/-2 to 25+/-2 mm Hg; P<0.05), and pulmonary capillary wedge pressure (25+/-2 to 20+/-2 mm

112 enous pressure (15 vs. 13 mm Hg; p = 0.001), pulmonary capillary wedge pressure (29 vs. 24 mm Hg; p =

113 ues, dipyridamole resulted in an increase in pulmonary capillary wedge pressure (54 +/- 78% vs. 32 +/

114 rimary composite efficacy end point included pulmonary capillary wedge pressure (72 to 96 hours) and

115 nduced significant dose-related decreases in pulmonary capillary wedge pressure (average change -5.9+

116 iac output and steeper increases in exercise pulmonary capillary wedge pressure (both P<0.0001).

117 (CHF, 48+/-12; LVAD, 30+/-5 mm Hg) and mean pulmonary capillary wedge pressure (CHF, 31+/-11; LVAD,

118 - 5 ml/beat per min, p < 0.01) and increased pulmonary capillary wedge pressure (from 25 +/- 2 to 29

119 mm Hg increase; P = 0.022), diastolic PAP - pulmonary capillary wedge pressure (HR, 2.19; 95% CI, 1.

120 ndicator of hemodynamic severity is the mean Pulmonary Capillary Wedge Pressure (mPCWP), which is ide

121 However, elevation of the pulmonary capillary wedge pressure (n=8142) had a larger

122 ection fraction (p = 0.02, r = 0.83), higher pulmonary capillary wedge pressure (p = 0.01, r = 0.58)

123 on fraction (p = 0.008, r = 0.88) and higher pulmonary capillary wedge pressure (p = 0.02, r =0.54).

124 reduction in the workload corrected exercise pulmonary capillary wedge pressure (P<0.01).

125 hanges in right atrial pressure (P=0.36) and pulmonary capillary wedge pressure (P=0.53) were not.

126 (2)) was measured by intraarterial catheter, pulmonary capillary wedge pressure (Pcw), continuous car

127 (cardiac index < or =2.5 l/min per m(2) and pulmonary capillary wedge pressure (PCWP) > or =15 mm Hg

128 of right atrial pressure (RAP) >12 mm Hg or pulmonary capillary wedge pressure (PCWP) >15 mm Hg were

129 decreases in creatinine (2.6 to 1.5 mg/dL), pulmonary capillary wedge pressure (PCWP) (32 to 14 mm H

130 d, grouping patients by baseline measures of pulmonary capillary wedge pressure (PCWP) and cardiac in

131 ad as shown by significant increases in both pulmonary capillary wedge pressure (PCWP) and central ve

132 to have a strong positive relationship with pulmonary capillary wedge pressure (PCWP) and left ventr

133 Functional capacity, and dynamic pulmonary capillary wedge pressure (PCWP) and right atri

134 significant relations were observed between pulmonary capillary wedge pressure (PCWP) and sole param

135 s were placed in 11 subjects for measures of pulmonary capillary wedge pressure (PCWP) and SV (thermo

136 Although right atrial pressure (RAP) and pulmonary capillary wedge pressure (PCWP) are correlated

137 In the prospective group, pulmonary capillary wedge pressure (PCWP) derived as: PC

138 ppler echocardiography, BNP measurement, and pulmonary capillary wedge pressure (PCWP) determination.

139 Increases in pulmonary capillary wedge pressure (PCWP) develop in pat

140 A marked rise in pulmonary capillary wedge pressure (PCWP) during exertio

141 lic velocity (E/Ea) has been correlated with pulmonary capillary wedge pressure (PCWP) in a wide vari

142 es (BNP) can serve as noninvasive markers of pulmonary capillary wedge pressure (PCWP) in the setting

143 During exercise, pulmonary capillary wedge pressure (PCWP) increased mark

144 ional capacity, quality of life, and dynamic pulmonary capillary wedge pressure (PCWP) responses were

145 t of 60 patients had invasive measurement of pulmonary capillary wedge pressure (PCWP) simultaneous w

146 The eoPH and ePVH groups had higher pulmonary capillary wedge pressure (PCWP) than the ePH g

147 The primary outcome was ratio of pulmonary capillary wedge pressure (PCWP) to cardiac ind

148 Pulmonary capillary wedge pressure (PCWP) was estimated

149 ardiac index, pulmonary artery pressure, and pulmonary capillary wedge pressure (PCWP) were recorded.

150 th group 3 disease, 27% (n=161) had elevated pulmonary capillary wedge pressure (PCWP) with postcapil

151 ft ventricular ejection fraction, 22 +/- 9%; pulmonary capillary wedge pressure (PCWP), 16 +/- 10 mm

152 of renal sympathetic nerve activity (RSNA), pulmonary capillary wedge pressure (PCWP), and mean arte

153 ation was performed in eight males from whom pulmonary capillary wedge pressure (PCWP), central venou

154 entricular filling pressure, as expressed by pulmonary capillary wedge pressure (PCWP), during lower-

155 D, Corvia Medical) was associated with lower pulmonary capillary wedge pressure (PCWP), fewer symptom

156 We measured pulmonary capillary wedge pressure (PCWP), SV, left vent

157 All doses of istaroxime lowered pulmonary capillary wedge pressure (PCWP), the primary e

158 duration had significant relations with mean pulmonary capillary wedge pressure (PCWP).

159 endent association between the reductions in pulmonary capillary wedge pressure (PCWP; 25.4, 24.6, 24

160 and compared them by linear regression with pulmonary capillary wedge pressure (pw).

161 orrelated significantly with changes in mean pulmonary capillary wedge pressure (r=0.63, P<0.001).

162 CS CNP levels correlated with mean pulmonary capillary wedge pressure (r=0.82, P=0.007).

163 as expressed as transmural filling pressure (pulmonary capillary wedge pressure - right atrial pressu

164 ance 24%, pulmonary vascular resistance 25%, pulmonary capillary wedge pressure 33%, and central veno

165 pressure [RAP] 10 mm Hg and LV congestion if pulmonary capillary wedge pressure [PCWP] 22 mm Hg) cate

166 ance, whereas levels of ADMA correlated with pulmonary capillary wedge pressure and both systolic and

167 ak exercise, KE treatment markedly decreased pulmonary capillary wedge pressure and improved pressure

168 e, included higher right atrial pressure and pulmonary capillary wedge pressure and lower cardiac ind

169 Pulmonary capillary wedge pressure and LV end-diastolic

170 ventricular (LV) pressure-volume curves from pulmonary capillary wedge pressure and LV end-diastolic

171 Pulmonary capillary wedge pressure and LV end-diastolic

172 age- and sex-related normative responses of pulmonary capillary wedge pressure and mean pulmonary ar

173 on fraction exhibit the largest increases in pulmonary capillary wedge pressure and mean pulmonary ar

174 ressure >25 mmHg in the presence of a normal pulmonary capillary wedge pressure and portal hypertensi

175 Tezosentan also dose-dependently reduced pulmonary capillary wedge pressure and pulmonary and sys

176 te analysis, cardiopulmonary exercise tests, pulmonary capillary wedge pressure and serum sodium were

177 eous MCS normalized hemodynamics in AMI-VSD, pulmonary capillary wedge pressure and shunting were wor

178 Extracorporeal membrane oxygenation worsened pulmonary capillary wedge pressure and shunting, which c

179 nd-diastolic volume and Starling curves from pulmonary capillary wedge pressure and SV during lower b

180 tal effect on cardiac output, stroke volume, pulmonary capillary wedge pressure and systemic vascular

181 e with shock, pulmonary artery catheter use, pulmonary capillary wedge pressure and the incidence of

182 y requiring renal replacement therapy, lower pulmonary capillary wedge pressure and vasoactive-inotro

183 Higher pulmonary capillary wedge pressure appears to enhance ne

184 lted in a significantly greater reduction in pulmonary capillary wedge pressure at 3, 4, and 8 hours

185 diography, but there was no effect of age on pulmonary capillary wedge pressure at any point througho

186 ction fraction higher than 40%, and a raised pulmonary capillary wedge pressure at rest (>15 mm Hg) o

187 After 9 weeks there were no differences in pulmonary capillary wedge pressure at rest (13+/-4 versu

188 ratio was correlated with directly measured pulmonary capillary wedge pressure at rest (r=0.63, P<0.

189 0.3) during the 4-hour period and decreased pulmonary capillary wedge pressure at rest by 1 mm Hg (9

190 , 31 (52%) of 60 patients had a reduction in pulmonary capillary wedge pressure at rest, 34 (58%) of

191 s in body size, blood pressure, and baseline pulmonary capillary wedge pressure between groups (eg, p

192 2.6-3.8 L.min(-1).m(-2)]; P<0.001) and mean pulmonary capillary wedge pressure decreased (from 15 mm

193 x increased 70.6% by 48 hours after implant, pulmonary capillary wedge pressure decreased 44%, system

194 artery mean pressure decreased 19% (P=0.03), pulmonary capillary wedge pressure decreased 46% (P=0.00

195 peratively, the cardiac index increased 43%, pulmonary capillary wedge pressure decreased 52%, system

196 4% (17+/-4 versus 11+/-5 mm Hg, P<0.001) and pulmonary capillary wedge pressure decreased by 27% (31+

197 rom 38.3 +/- 1.6 to 25.9 +/- 1.7 mm Hg; mean pulmonary capillary wedge pressure decreased from 25.1 +

198 Pulmonary capillary wedge pressure decreased from 28.5+/

199 Pulmonary capillary wedge pressure decreased from 28.8+/

200 d pulmonary hypertension (n=1009) and normal pulmonary capillary wedge pressure displayed a consisten

201 ases in BP were correlated with reduction in pulmonary capillary wedge pressure during exercise (r=0.

202 The primary end point was the pulmonary capillary wedge pressure during exercise.

203 pressure at rest, 34 (58%) of 59 had a lower pulmonary capillary wedge pressure during exertion, and

204 2 mm Hg) or controls (9+/-2 mm Hg) displayed pulmonary capillary wedge pressure elevation (P=0.03).

205 Exercise elicits greater pulmonary capillary wedge pressure elevation compared wi

206 /Ea) greater than 10 is predictive of a mean pulmonary capillary wedge pressure greater than 15 mm Hg

207 The mean pulmonary capillary wedge pressure in patients with PHTN

208 In healthy subjects, pulmonary capillary wedge pressure increased from 10+/-2

209 Mean pulmonary capillary wedge pressure increased from 9.3 +/

210 l pressure, pulmonary arterial pressure, and pulmonary capillary wedge pressure increased similarly w

211 re paradoxically increase stroke volume when pulmonary capillary wedge pressure is lowered with vasod

212 A pulmonary capillary wedge pressure of >=15 mm Hg indicat

213 preserved cardiac index (2.4 liters/min.m2), pulmonary capillary wedge pressure of 16 +/- 9 mm Hg (me

214 monary artery pressure of 40.5+/-11.4 mm Hg, pulmonary capillary wedge pressure of 22.6+/-8.9 mm Hg,

215 ass IV, cardiac index of 1.7 L/min per m(2), pulmonary capillary wedge pressure of 25.6 mm Hg, and le

216 any level of cardiac filling volume was the pulmonary capillary wedge pressure of the seniors lower

217 .23; SE, 0.01; P<0.001), higher right atrium:pulmonary capillary wedge pressure ratio (beta, 0.25; SE

218 Impella 5.0 provided the greatest degree of pulmonary capillary wedge pressure reductions and decrea

219 ion fraction exhibited a steeper increase in pulmonary capillary wedge pressure relative to infused v

220 Older women displayed a steeper increase in pulmonary capillary wedge pressure relative to volume in

221 The mean pulmonary capillary wedge pressure rose from 25+/-14 to

222 <35 seconds) demonstrated elevated exercise pulmonary capillary wedge pressure to cardiac output slo

223 At week 12, the change in 25-W pulmonary capillary wedge pressure was -2.8 (6.8) mm Hg

224 (6-17) mm Hg, CVP was 8.5 (6-18) mm Hg, and pulmonary capillary wedge pressure was 18 (14-21) mm Hg.

225 ary artery saturations were 46.7+/-9.2%, and pulmonary capillary wedge pressure was 26.2+/-7.6 mm Hg.

226 x was 1.39 +/- 0.43 L . min(-)(1) . m(-)(2), pulmonary capillary wedge pressure was 31.5 +/- 5.7 mm H

227 )) was 21.6 +/- 4 mL . kg(-)(1) . min(-)(1), pulmonary capillary wedge pressure was 5.9 +/- 4.6 mm Hg

228 VP and CVP was 0.4 mm Hg and between PVP and pulmonary capillary wedge pressure was 7.5 mm Hg.

229 Pulmonary capillary wedge pressure was correlated with b

230 heart rate, systemic vascular resistance and pulmonary capillary wedge pressure was evident at 3 min

231 Mean exercise pulmonary capillary wedge pressure was lower at 6 months

232 Pulmonary capillary wedge pressure was reduced from a me

233 fraction were similar for the two groups but pulmonary capillary wedge pressure was slightly lower fo

234 After study drug administration, exercise pulmonary capillary wedge pressure was substantially imp

235 Furthermore, pulmonary capillary wedge pressure was superior to therm

236 y artery catheterization with measurement of pulmonary capillary wedge pressure waveform during 5 dif

237 tly by performing a detailed analysis of the pulmonary capillary wedge pressure waveform obtained by

238 creased and systemic vascular resistance and pulmonary capillary wedge pressure were decreased, as co

239 e highly correlated (r=0.947), while PVP and pulmonary capillary wedge pressure were found to be mode

240 P), mean pulmonary artery pressure (PAP) and pulmonary capillary wedge pressure were obtained by stan

241 from the right atrium, pulmonary artery, and pulmonary capillary wedge pressure were obtained in 85 p

242 ion, HFpEF subjects displayed an increase in pulmonary capillary wedge pressure with exercise from 20

243 TR subjects displayed higher pulmonary capillary wedge pressure with exercise, but th

244 action, augments cardiac output, and reduces pulmonary capillary wedge pressure without causing delet

245 ation of elevated cardiac filling pressures (pulmonary capillary wedge pressure).

246 Pulmonary capillary wedge pressure* decreased to a large

247 lity ratio (>1.6; n=42; median RAP, 4 mm Hg; pulmonary capillary wedge pressure, 11 mm Hg), those wit

248 ; Fick cardiac output, 11.4+/-3.3 L/min; and pulmonary capillary wedge pressure, 13+/-4 mm Hg.

249 ity ratio (<=1.6; n=58; median RAP, 8 mm Hg; pulmonary capillary wedge pressure, 22 mm Hg; P<0.0001 f

250 8 cm; end-systolic diameter, 3.53+/-0.51 cm; pulmonary capillary wedge pressure, 8.1+/-3.1 mm Hg; pul

251 and 79% had elevated right atrial pressure, pulmonary capillary wedge pressure, and pulmonary hypert

252 en shown to improve cardiac output, decrease pulmonary capillary wedge pressure, and reduce pulmonary

253 jection fraction and cardiac index, elevated pulmonary capillary wedge pressure, and renal impairment

254 Primary end point was pulmonary capillary wedge pressure, and secondary end po

255 BP, cardiac output, heart rate, pulmonary capillary wedge pressure, and systemic vascula

256 uding measured and calculated values such as pulmonary capillary wedge pressure, aortic pulsatility i

257 hat this relation may be changed by elevated pulmonary capillary wedge pressure, augmenting right ven

258 iac performance, improving cardiac index and pulmonary capillary wedge pressure, but statistical sign

259 oss the spectrum of systemic blood pressure, pulmonary capillary wedge pressure, cardiac index, and e

260 ffect on heart rate, mean arterial pressure, pulmonary capillary wedge pressure, cardiac index, or sy

261 ted statistically significant differences in pulmonary capillary wedge pressure, cardiac output, pulm

262 Elevated LV end-diastolic or pulmonary capillary wedge pressure, consistent with dias

263 n on echocardiography, ratio of right atrial/pulmonary capillary wedge pressure, hemoglobin) was crea

264 ials in congestive heart failure to decrease pulmonary capillary wedge pressure, improve cardiac outp

265 The pulmonary capillary wedge pressure, lactic acid level, a

266 face area, cardiac index, ejection fraction, pulmonary capillary wedge pressure, left ventricular dim

267 ubgroup, left atrial dilatation, increase of pulmonary capillary wedge pressure, PAP and RAP were mor

268 Pulmonary capillary wedge pressure, pulmonary arterial p

269 ured included cardiac output, stroke volume, pulmonary capillary wedge pressure, systemic and pulmona

270 ted pulmonary vascular resistance and normal pulmonary capillary wedge pressure, we make a weak recom

271 ncrease in estimated trans-septal gradient (=pulmonary capillary wedge pressure-right atrial pressure

272 However, LV transmural pressure (pulmonary capillary wedge pressure-right atrial pressure

273 ering mean arterial pressure, heart rate, or pulmonary capillary wedge pressure.

274 ly associated with worse symptoms and higher pulmonary capillary wedge pressure.

275 duce systemic vascular resistance as well as pulmonary capillary wedge pressure.

276 ient, left ventricular systolic pressure and pulmonary capillary wedge pressure.

277 r flow propagation velocities for estimating pulmonary capillary wedge pressure.

278 heir diastolic pulmonary artery pressure and pulmonary capillary wedge pressure.

279 ween diastolic pulmonary artery pressure and pulmonary capillary wedge pressure.

280 nadequate LV diastolic filling, despite high pulmonary capillary wedge pressure.

281 e infusion with simultaneous measurements of pulmonary capillary wedge pressure.

282 pulmonary fibrosis, patient age, and varying pulmonary capillary wedge pressure.

283 essure: 105 +/- 12 mm Hg to 98 +/- 13 mm Hg; pulmonary capillary wedge pressure: 17 +/- 6 mm Hg to 21

284 capillary wedge pressure between groups (eg, pulmonary capillary wedge pressure: LVH, 13.4+/-2.7 vers

285 ween different echocardiographic indices and pulmonary capillary wedge pressures (PCWP) in normal vol

286 Pulmonary capillary wedge pressures and left ventricular

287 Pulmonary capillary wedge pressures and LV end-diastolic

288 Right atrial and pulmonary capillary wedge pressures increased from 6 +/-

289 on had higher resting pulmonary arterial and pulmonary capillary wedge pressures than the remaining h

290 OMA+D decreased pulmonary arterial and pulmonary capillary wedge pressures to a greater level t

291 arterial, pulmonary artery, right atrial and pulmonary capillary wedge pressures, cardiac index, syst

292 re are further rises in pulmonary artery and pulmonary capillary wedge pressures, suggesting abnormal

293 stration did not change systemic arterial or pulmonary capillary wedge pressures.

294 systemic, right atrial, pulmonary artery, or pulmonary capillary wedge pressures; cardiac index; resp

295 e (non-failing), BNP lowered central venous, pulmonary capillary wedge, diastolic, mean pulmonary art

296 osimendan caused dose-dependent decreases in pulmonary capillary wedge, right atrial, pulmonary arter

297 030 microg per kilogram per minute decreased pulmonary-capillary wedge pressure by 6.0 and 9.6 mm Hg,

298 of a Swan-Ganz catheter, 127 patients with a pulmonary-capillary wedge pressure of 18 mm Hg or higher

299 The cardiac index and pulmonary-capillary wedge pressure were elevated in the

300 arterial pressures, and it had no effect on pulmonary-capillary wedge pressure, right atrial pressur